KYTHERA Biopharmaceuticals Announces Pricing of Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- KYTHERA
Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the pricing of
its underwritten public offering of 2,604,168 shares of its common
stock at a price to the public of $48.00 per share, before underwriting
discounts and commissions and expenses of the offering, for gross
proceeds of approximately $125 million. All of the shares of the common
stock sold in the offering were offered by KYTHERA. In addition,
KYTHERA granted the underwriters a 30-day option to purchase up to an
additional 390,625 shares.

KYTHERA intends to use the substantial majority of the net proceeds of
the offering to fund the ongoing development and preparation for
potential commercialization of ATX-101, and the balance for working
capital and general corporate purposes, including research and
development, which may include repayments of outstanding amounts under
KYTHERA's credit facility.

The offering is expected to close on March 16, 2015, subject to
satisfaction of customary closing conditions.

Goldman, Sachs & Co., BofA Merrill Lynch, and Leerink Partners acted as
the joint book-running managers for the offering. Cowen and Company
acted as co-manager.

The offering was made only by means of a prospectus and pursuant to a
shelf registration statement declared effective by the Securities and
Exchange Commission on November 6, 2014. Copies of the prospectus and
related prospectus supplement relating to the offering may be obtained,
when available, by contacting Goldman, Sachs & Co., Attention:
Prospectus Department, 200 West Street, New York, NY 10282, or by
telephone at (866) 471-2526 or e-mail at [email protected]; or BofA
Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New
York, NY10038, or by email at [email protected]; or
Leerink Partners, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, MA 02110, or by phone at (800) 808-7525, ext. 6142,
or by email at [email protected]

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.

About KYTHERA

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization of
novel prescription products for the aesthetic medicine market.
KYTHERA's lead product candidate, ATX-101, is currently in late-stage
clinical development as an injectable treatment for the improvement of
submental fullness, which commonly presents as a double chin, and is a
potential first-in-class submental contouring injectable drug. The FDA
has determined the NDA will have a Prescription Drug User Fee Act
(PDUFA) action date of May 13, 2015. In addition to its lead product
candidate ATX-101, KYTHERA also licensed the worldwide rights to
setipiprant, an early-stage potential treatment for hair loss. KYTHERA
also maintains an active research interest in fat biology, pigmentation
modulation and facial contouring.

Forward-Looking Statements

To the extent that statements contained in this press release are not
descriptions of historical facts regarding KYTHERA, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve substantial risks and uncertainties
that could cause our actual results, performance or achievements to
differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among
others, the timing and size of the offering, the conditions affecting
the capital markets, general economic, industry, or political
conditions, and the satisfaction of customary closing conditions
related to the proposed public offering. KYTHERA undertakes no
obligation to update or revise any forward-looking statements. For a
further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of the company in
general, see the prospectus supplement and accompanying prospectus for
this offering included on Form 424(b)(5) as part of the Registration
Statement on Form S-3/A filed by KYTHERA on November 6, 2014, as well
as KYTHERA 's Annual Report on Form 10-K for the year ended December
31, 2014 and its other reports filed with the Securities and Exchange
Commission.


CONTACT: Investor Contact:
Heather Rowe
Director, Investor Relations
Tel: (818) 587- 4559
[email protected]

Suggested Articles

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.